Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Avonex drug warning letter, severe hypatic injury
Patient trial of immunization to treat Alzheimer’s disease begins at Cedars-Sinai
Interferon-ß-related tumefactive brain lesion in a Caucasian patient with neuromyelitis optica and clinical stabilization with tocilizumab.
Trimesta (Oral Estriol)
Genetic analysis of aquaporin-4 in neuromyelitis optica.
American Neurological Association Annual 2012 Annual Meeting
Brain-gut axis and pentadecapeptide BPC 157. Theoretical and practical implications.
Efficacy and Safety of Fingolimod in Hispanic Patients with Multiple Sclerosis: Pooled Clinical Trial Analyses.
Interrater Reliability of Four Sensory Measures in People with Multiple Sclerosis.
Decision making under uncertainty, therapeutic inertia, and physicians' risk preferences in the management of multiple sclerosis (DIScUTIR MS).
Neurological involvement in Primary Sjögren Syndrome.
Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study.
Effect of vitamin D on MS activity by disease-modifying therapy class.
UCSF Seminar: "The needle in the haystack: Searching for target antigens of the adaptive immune response in MS."
Keystone Symposium: T Cells: Regulation and Effector Function
CombiRx for MS not better than monotherapy
Daclizumab in multiple sclerosis: a high-yield extension study.
The impact of sexual dysfunction on health-related quality of life in people with multiple sclerosis.
Fumaric acid esters prevent the NLRP3 inflammasome-mediated and ATP-triggered pyroptosis of differentiated THP-1 cells.
Tumor necrosis factor-α impairs oligodendroglial differentiation through a mitochondria-dependent process.
Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial.
Eosinophilic Fasciitis-like Disorder Developing in the Setting of Multiple Sclerosis Therapy.
Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes.
Multimodal quantitative MRI assessment of cortical damage in relapsing-remitting multiple sclerosis.
The immunosuppressant leflunomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis.

Pages